<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2398">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344444</url>
  </required_header>
  <id_info>
    <org_study_id>COVID 2020-001</org_study_id>
    <nct_id>NCT04344444</nct_id>
  </id_info>
  <brief_title>Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease</brief_title>
  <acronym>RCT</acronym>
  <official_title>Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LCMC Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LCMC Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected&#xD;
      patients with early moderate and severe disease admitted to the hospital and randomized to&#xD;
      one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine&#xD;
      alone, OR hydroxychloroquine and azithromycin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 study.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      â€¢ To evaluate clinical outcomes in patients with suspected or confirmed COVID-19 with early&#xD;
      moderate to severe disease in a randomized controlled trial.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate quantitative viral load over time&#xD;
&#xD;
        -  To evaluate length of hospital stay and days in ICU&#xD;
&#xD;
        -  To evaluate toxicity of the treatment options&#xD;
&#xD;
        -  To evaluate rate of readmission after hospital discharge&#xD;
&#xD;
        -  To evaluate duration of clinical symptoms&#xD;
&#xD;
      Arm A:&#xD;
&#xD;
      Control Arm - Supportive Care Only&#xD;
&#xD;
      Arm B:&#xD;
&#xD;
      Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5&#xD;
&#xD;
      Arm C:&#xD;
&#xD;
      Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po&#xD;
      days 2 through 5&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Anticipated">December 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Most severe outcome</measure>
    <time_frame>5 days</time_frame>
    <description>ordinal outcome of most severe a patient experienced after inpatient admission</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Supportive Care only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>tablets provided as described in Arm B</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>tablets provided as described in Arm C</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than 18 years&#xD;
&#xD;
          -  Positive SARS-CoV-2 testing or consistent clinical syndrome (based on clinical picture&#xD;
             e.g. characteristic infiltrates on chest x-ray, laboratory findings, and with&#xD;
             agreement by two physicians) in patients under investigation (PUIs).&#xD;
&#xD;
          -  Onset of symptoms &lt; 7 days from date of enrollment&#xD;
&#xD;
          -  Oxygen saturation of &gt;94% on room air with defined risk factors (Table 1) consistent&#xD;
             with moderate disease OR oxygen saturation of &lt; 94% on room air consistent with severe&#xD;
             disease&#xD;
&#xD;
          -  Ability and willingness to comply with study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  QTc greater than 450 milliseconds on screening EKG&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Inability to take oral pills or inability to use a feeding tube&#xD;
&#xD;
          -  Inability to obtain informed consent either from the patient or from the next of kin&#xD;
             if patient is incapacitated. For the purpose of this study obtaining a verbal consent&#xD;
             from a family member on the phone with a witness will be considered acceptable since&#xD;
             there is a 'no visitor' policy in force at hospitals.&#xD;
&#xD;
          -  Patients requiring ICU level care&#xD;
&#xD;
          -  use of azithromycin or hydroxychloroquine within 30 days prior to admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meredith Clement, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSUHSC/UMCNO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

